


**Product Name** : CB-839  
**Cat. No.** : PC-42933  
**CAS No.** : 1439399-58-2  
**Molecular Formula** : C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub>S  
**Molecular Weight** : 571.5741  
**Target** : Glutaminase  
**Solubility** : DMSO: ≥ 30 mg/mL



## Biological Activity

CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of **glutaminase** with IC<sub>50</sub> of 28 and 23 nM for glutaminase in kidney and brain (GAC and KGA), but not the liver form of glutaminase (GLS2, IC<sub>50</sub>>1 μM).

CB-839 (Telaglenastat) demonstrates antiproliferative activity in triple-negative breast cancer (TNBC) cell line HCC-1806 and MDA-MB-231 with IC<sub>50</sub> of 20-55 nM.

CB-839 (Telaglenastat) decreases glutamine consumption, glutamate production, oxygen consumption, and the steady-state levels of glutathione and several tricarboxylic acid cycle intermediates.

CB-839 (Telaglenastat) exhibits vivo efficacy in breast cancer xenograft models, both as a single agent and in combination with paclitaxel.

## References

Gross MI, et al. *Mol Cancer Ther.* 2014 Apr;13(4):890-901.

Jacque N, et al. *Blood.* 2015 Sep 10;126(11):1346-56.

Chakrabarti G, et al. *Cancer Metab.* 2015 Oct 12;3:12.

Zimmermann SC, et al. *ACS Med Chem Lett.* 2016 Mar 13;7(5):520-4.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com